CN118891525A - 用于抗trop2抗体-药物缀合物疗法的评分方法 - Google Patents

用于抗trop2抗体-药物缀合物疗法的评分方法 Download PDF

Info

Publication number
CN118891525A
CN118891525A CN202380027572.6A CN202380027572A CN118891525A CN 118891525 A CN118891525 A CN 118891525A CN 202380027572 A CN202380027572 A CN 202380027572A CN 118891525 A CN118891525 A CN 118891525A
Authority
CN
China
Prior art keywords
cancer
adc
optical density
antibody
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380027572.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·斯皮茨穆勒
G·施密特
N·特里奇
A·卡皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Daiichi Sankyo Co Ltd
Original Assignee
AstraZeneca UK Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, Daiichi Sankyo Co Ltd filed Critical AstraZeneca UK Ltd
Publication of CN118891525A publication Critical patent/CN118891525A/zh
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
CN202380027572.6A 2022-03-16 2023-03-14 用于抗trop2抗体-药物缀合物疗法的评分方法 Pending CN118891525A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320629P 2022-03-16 2022-03-16
US63/320629 2022-03-16
PCT/IB2023/052428 WO2023175483A1 (en) 2022-03-16 2023-03-14 A scoring method for an anti-trop2 antibody‑drug conjugate therapy

Publications (1)

Publication Number Publication Date
CN118891525A true CN118891525A (zh) 2024-11-01

Family

ID=85776040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380027572.6A Pending CN118891525A (zh) 2022-03-16 2023-03-14 用于抗trop2抗体-药物缀合物疗法的评分方法

Country Status (8)

Country Link
EP (1) EP4493933A1 (https=)
JP (1) JP2025509564A (https=)
KR (1) KR20240165390A (https=)
CN (1) CN118891525A (https=)
AU (1) AU2023235490A1 (https=)
CA (1) CA3255700A1 (https=)
IL (1) IL315662A (https=)
WO (1) WO2023175483A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119986001A (zh) * 2025-01-23 2025-05-13 中山大学孙逸仙纪念医院 试剂盒及其在预测trop2-adc疗效中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026052764A1 (en) 2024-09-06 2026-03-12 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody drug conjugate therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE198623T1 (de) 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
IN2014DN06806A (https=) 2012-02-10 2015-05-22 Univ Maryland
ITCH20120008A1 (it) * 2012-05-16 2013-11-17 Saverio Alberti Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
US10241115B2 (en) * 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
AU2014371934B2 (en) * 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
JP6980980B2 (ja) * 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
CN108601841A (zh) * 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
CN110461342A (zh) * 2017-02-06 2019-11-15 诺华股份有限公司 预测对免疫疗法的反应的方法
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119986001A (zh) * 2025-01-23 2025-05-13 中山大学孙逸仙纪念医院 试剂盒及其在预测trop2-adc疗效中的应用
CN119986001B (zh) * 2025-01-23 2026-04-07 中山大学孙逸仙纪念医院 试剂盒及其在预测trop2-adc疗效中的应用

Also Published As

Publication number Publication date
JP2025509564A (ja) 2025-04-11
IL315662A (en) 2024-11-01
WO2023175483A1 (en) 2023-09-21
KR20240165390A (ko) 2024-11-22
CA3255700A1 (en) 2023-09-21
AU2023235490A1 (en) 2024-09-26
EP4493933A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
WO2021260583A1 (en) Combination of antibody-drug conjugate and dna-pk inhibitor
AU2021340002B2 (en) A scoring method for an anti-her2 antibody-drug conjugate therapy
TWI822822B (zh) 抗體-藥物結合物之用途
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
WO2022102695A1 (ja) 抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療
JP4799863B2 (ja) 癌制御方法
CN118891525A (zh) 用于抗trop2抗体-药物缀合物疗法的评分方法
EP4676541A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
CN119403829A (zh) 对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
WO2026052764A1 (en) A scoring method for an anti-trop2 antibody drug conjugate therapy
US20250288687A1 (en) Combination of antibody-drug conjugates and dnmt inhibitors
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合
HK40045208A (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate
EA045144B1 (ru) Лечение her2-мутированного рака введением конъюгата анти-her2-антитело-лекарственное средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination